Valneva SE (VALN) has a near-term catalyst to watch related to its tetravalent Shigella vaccine candidate, S4V2, developed in partnership with LimmaTech Biologics.
Shigellosis, caused by Shigella bacteria, is the second leading cause of fatal diarrheal disease worldwide, responsible for an estimated 600,000 deaths annually, particularly among children in low-and middle-income countries. Despite this burden, no approved Shigella vaccine currently exists, making S4V2 the most clinically advanced candidate in development.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.